Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-903 Form 1 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment
Cmax of ABBV-903
Tmax of ABBV-903
Terminal phase elimination half-life of ABBV-903
AUCt of ABBV-903
AUCinf of ABBV-903
| Arm | Type | Description |
|---|---|---|
| Part 1: Sequence A | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after a high fat meal. Participants will be followed up for 30 days. |
| Part 1: Sequence B | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Participants will be followed up for 30 days. |
| Part 2: Sequence A | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after a high fat meal. Participants will be followed up for 30 days. |
| Part 2: Sequence B | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Participants will be followed up for 30 days. |
| Name | Type | Description |
|---|---|---|
| ABBV-903 Tablet Form 1 | DRUG | Oral Tablets |
| ABBV-903 Tablet Form 2 | DRUG | Oral Tablets |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32 kg/m2 after rounding to the tenth. * Negative test result for SARS-CoV-2 infection at screening visit and upon initial confinement. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, labor...
ABBV-903 Form 1 is an investigational small molecule being developed by AbbVie Inc. It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers to assess the relative bioavailability of immediate release formulations of ABBV-903.
ABBV-903 Form 1 is being studied for use in healthy volunteers. The purpose of the clinical trial is to assess the relative bioavailability of immediate release formulations of ABBV-903 in healthy adult participants. It is not yet approved for any medical condition.
ABBV-903 Form 1 is being developed by AbbVie Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's bioavailability in healthy volunteers. AbbVie's stock ticker is ABBV.
ABBV-903 Form 1 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. It is currently being studied in a completed Phase 1 trial involving healthy adult participants.
ABBV-903 Form 1 is associated with clinical trial NCT05836506, titled 'A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants.' This Phase 1 trial was conducted in the United States and has been completed.
ABBV-903 Form 1 is a specific formulation of ABBV-903. The clinical trial NCT05836506 evaluates immediate release formulations of ABBV-903, including Form 1, to compare their relative bioavailability. The drug is being developed by AbbVie Inc.